Hht Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-12-2024
- Paid Up Capital ₹ 0.10 M
as on 30-12-2024
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 109.32%
(FY 2022)
- Profit 111.44%
(FY 2022)
- Ebitda 136.24%
(FY 2022)
- Net Worth 105.37%
(FY 2022)
- Total Assets 38.52%
(FY 2022)
About Hht Pharma
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rama Mallareddy and Gangisetty Chakravarthy serve as directors at the Company.
- CIN/LLPIN
U74999TG2018PTC128617
- Company No.
128617
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Hht Pharma Private Limited offer?
Hht Pharma Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Brain & Nervous System Drugs, Immunomodulator Drugs, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Psychotherapeutic Agents, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Osteoporosis Medications.
Who are the key members and board of directors at Hht Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rama Mallareddy  | Director | 28-Nov-2018 | Current |
| Gangisetty Chakravarthy | Director | 28-Nov-2018 | Current |
Financial Performance of Hht Pharma.
Hht Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 109.32% increase. The company also saw a substantial improvement in profitability, with a 111.44% increase in profit. The company's net worth Soared by an impressive increase of 105.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hht Pharma?
In 2021, Hht Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Prakruthi Enviro Tech Solutions Private LimitedActive 7 years 1 monthRama Mallareddy and Gangisetty Chakravarthy are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hht Pharma?
Unlock and access historical data on people associated with Hht Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hht Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hht Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
